StreetInsider.com News Articles

Form NT 10-K Protagenic Therapeutics, For: Mar 31

Tue, 30 Jun 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260630/26711721.html

Form NT 10-K Protagenic Therapeutics, For: Mar 31

Tue, 30 Jun 2026 11:00:00 -0400

si-local-file:///var/storage/secattach/20260630/26711721.html

Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model

Tue, 30 Jun 2026 08:30:00 -0400

As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF₁ receptor antagonist did not show activity in the same model.

NEW YORK, NY / ACCESS Newswire / June 30, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company focused on novel neuropeptide therapies for stress-related disorders, today announced the publication of new preclinical data for its lead candidate, PT00114, in the peer-reviewed journal Behavioural Pharmacology. In a well-established rodent model of chronic unpredictable stress, PT00114 reduced both

Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model

Tue, 30 Jun 2026 08:30:00 -0400

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Tue, 19 May 2026 08:15:00 -0400

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regulatory affairs veteran Dr. Eric Floyd, Ph.D., MBA, as Regulatory Affairs Advisor, and DanforthHealth, a premier life science operational consulting firm, to establish institutional-grade operational processes and infrastructure. Together, these engagements reflect Protagenic's deliberate, lean operating model concentrating resources and expertise

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Tue, 19 May 2026 08:15:00 -0400

Protagenic Therapeutics names Bill Nichols Jr. as president

Thu, 23 Apr 2026 08:19:52 -0400

Protagenic Therapeutics Inc. (OTCQB: PTIX) appointed Bill Nichols Jr. as president to lead the company's clinical development efforts for its experimental drug PT00114, according to a company statement.

Nichols brings more than 20 years of executive experience in neuroscience and rare disease therapeutics from roles at bluebird bio, Dova Pharmaceuticals, and Bristol-Myers Squibb. At Protagenic, he will oversee clinical development and corporate strategy as the company prepares to begin Phase 2 enrollment for PT00114 in 2026.

PT00114 targets the teneurin C-terminal associated peptide pathway for treating stress-related neuropsychiatric disorders including anxiety, PTSD, and treatment-resistant depression. The company reported positive Phase 1 safety

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

Thu, 23 Apr 2026 08:15:00 -0400

NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the Company's management structure, sharpens focus and resources on advancing its lead candidate, PT00114 - positioning Protagenic for accelerated clinical progress and long-term value creation for patients and shareholders alike.

Mr. Nichols brings more than two decades of senior leadership experience spanning strategy, commercial operations, market

Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114

Thu, 23 Apr 2026 08:15:00 -0400

Mr. Nichols brings more than two decades of senior leadership experience spanning strategy, commercial operations, market

Form 8-K Protagenic Therapeutics, For: Mar 31

Tue, 07 Apr 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260407/26280288.html

Form 8-K Protagenic Therapeutics, For: Mar 31

Tue, 07 Apr 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260407/26280288.html

Protagenic completes Phytanix separation, reduces liabilities by $6.3 million

Tue, 17 Mar 2026 08:04:13 -0400

Protagenic Therapeutics Inc. (OTCQB: PTIX) completed a settlement and separation related to its Phytanix Bio acquisition, removing more than $6.3 million in liabilities from its balance sheet and canceling 117,690 common shares issued in connection with the transaction.

The biopharmaceutical company reported that total liabilities decreased from approximately $6.8 million to approximately $0.5 million following the separation. The transaction also eliminated more than $1 million in annualized costs associated with Phytanix operations.

Common shares outstanding decreased from 1,934,878 shares as of November 26, 2025, to 1,810,208 shares as of March 5, 2026. The canceled merger shares represented approximately 6% of the November

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Tue, 17 Mar 2026 08:00:00 -0400

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114

NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders, today announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic's capital structure, materially reducing liabilities and sharpens the Company's operating focus on PT00114.

At the common-share level,

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Tue, 17 Mar 2026 08:00:00 -0400

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114

At the common-share level,

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Tue, 10 Mar 2026 08:00:00 -0400

Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026

NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety, today announced that its common stock has been upgraded from OTC Pink to the OTCQB^® and has commenced trading on OTCQB under the symbol "PTIX."

The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Tue, 10 Mar 2026 08:00:00 -0400

Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026

The OTCQB is a recognized public market for developing companies that meet defined reporting, management certification

Form 10-Q Protagenic Therapeutics, For: Dec 31

Mon, 09 Mar 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260309/26128995.html

Form 10-Q Protagenic Therapeutics, For: Dec 31

Mon, 09 Mar 2026 07:46:00 -0400

si-local-file:///var/storage/secattach/20260309/26128995.html

Form 8-K Protagenic Therapeutics, For: Feb 03

Tue, 03 Mar 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260303/26095905.html

Form 8-K Protagenic Therapeutics, For: Feb 03

Tue, 03 Mar 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260303/26095905.html

Form 8-K Protagenic Therapeutics, For: Feb 17

Tue, 24 Feb 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260224/26046160.html

Form 8-K Protagenic Therapeutics, For: Feb 17

Tue, 24 Feb 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260224/26046160.html

Form NT 10-Q Protagenic Therapeutics, For: Dec 31

Wed, 18 Feb 2026 06:49:00 -0400

si-local-file:///var/storage/secattach/20260218/26017505.html

Form NT 10-Q Protagenic Therapeutics, For: Dec 31

Wed, 18 Feb 2026 06:49:00 -0400

si-local-file:///var/storage/secattach/20260218/26017505.html

Form 25-NSE Protagenic Therapeutics, Filed by: Nasdaq Stock Market LLC

Fri, 23 Jan 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260123/25887880.html